Hospital de Santa Maria

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Target Physiotherapy Versus Exercise Support Intervention for Bladder-bowel Dysfunction in Adolescents With Obesity

  NCT07724158· University of Lisbon· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

  NCT07507760· Phase 2· PETHEMA Foundation· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives

  NCT07316621· GLSMED Learning Health S.A.· Source

• Recruiting

  EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

  NCT07262619· Phase 1/2· Eikon Therapeutics· Source

• Recruiting

  PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI

  NCT07343674· Portuguese Association of Interventional Cardiology· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

  NCT07054515· Phase 3· Azafaros B.V.· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants

  NCT06823466· University of L'Aquila· Source

• Recruiting

  Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection

  NCT06703632· ADVANCED MARKER DISCOVERY S.L.· Source

• Recruiting

  Xeltis Hemodialysis Access (aXess) Conduit: aXess-E Study

  NCT06329310· Xeltis· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

  NCT06559163· Phase 2· Zenas BioPharma (USA), LLC· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Recruiting

  Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

  NCT07159750· Hospital Universitari Vall d'Hebron Research Institute· Source

• Recruiting

  Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System

  NCT04861805· P+F Products + Features GmbH· Source

• Active, not recruiting

  Xeltis Hemodialysis Access Graft: aXess Pivotal Study

  NCT05473299· Xeltis· Source

• Recruiting

  Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

  NCT04924075· Phase 2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

  NCT03127267· Phase 3· AB Science· Source

• Recruiting

  LANDMARK Trial: a Randomised Controlled Trial of Myval THV

  NCT04275726· Meril Life Sciences Pvt. Ltd.· Source

• Active, not recruiting

  SyncAV Post-Market Trial

  NCT04100148· Abbott Medical Devices· Source

• Active, not recruiting

  Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

  NCT03366545· Biotronik SE & Co. KG· Source

• Active, not recruiting

  AMPLATZER PFO Occluder Post Approval Study

  NCT03309332· Abbott Medical Devices· Source

• Active, not recruiting

  A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

  NCT03148418· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  The European NAFLD Registry

  NCT04442334· Newcastle University· Source

• Active, not recruiting

  Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome

  NCT01934725· SECRETO Study Consortium· Source

• Recruiting

  Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

  NCT01574053· CHDI Foundation, Inc.· Source

• Enrolling by invitation

  EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV

  NCT02699736· Copenhagen University Hospital, Rigshospitalet· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Aortic stenosis3 recruiting
• Colorectal cancer3 recruiting
• Obesity3 recruiting
• Prostate cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Atrial fibrillation1 recruiting
• Bronchiectasis1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Crohn's disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Endometrial cancer1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Heart failure1 recruiting
• Hepatitis B1 recruiting
• Hepatitis C1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• Huntington's disease1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Neuroendocrine tumours1 recruiting
• Pancreatic cancer1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

  NCT06468527· Phase 2· Kors van der Ent· Source

• Completed

  BIOSTREAM.HF HeartInsight

  NCT05761249· Biotronik SE & Co. KG· Source

• Terminated

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· Phase 1/2· Amgen· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Safety and Performance of INVICTA Ventricular DF4 LEADS With Active Fixation-(APOLLO)

  NCT04590144· MicroPort CRM· Source

• Completed

  SAPIEN 3 Ultra EU PMS

  NCT04860752· Edwards Lifesciences· Source

• Completed

  Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy

  NCT04753749· MicroPort CRM· Source

• Completed

  Rostock International Parkinson's Disease Study (ROPAD)

  NCT03866603· CENTOGENE GmbH Rostock· Source

• Completed

  Confirm Rx Insertable Cardiac Monitor SMART Registry

  NCT03505801· Abbott Medical Devices· Source

• Terminated

  A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  NCT03452137· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

  NCT03371017· Phase 3· Hoffmann-La Roche· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Hoffmann-La Roche· Source

• Completed

  A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

  NCT02913456· Hoffmann-La Roche· Source

• Completed

  AMPLATZER™ Amulet™ LAA Occluder Trial

  NCT02879448· Abbott Medical Devices· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Hoffmann-La Roche· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Migraine17 works · 1 trial
• Hypertrophic cardiomyopathy10 works · 0 trials